NightBalance acquired by Royal Philips - Gilde Healthcare

NightBalance acquired by Royal Philips

7. Mai 2018

Utrecht, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired NightBalance, a portfolio company from specialist investor Gilde Healthcare. Netherlands-based NightBalance is a digital health scale-up company commercializing an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. With the acquisition of NightBalance, Philips expands its Sleep & Respiratory Care portfolio. Financial details of the transaction were not disclosed.

NightBalance’s Sleep Position Trainer (SPT) was designed as a patient friendly treatment alternative for people who suffer from positional obstructive sleep apnea. The SPT gently prompts them not to sleep on their back, avoiding the apneas from occurring during sleep. The SPT is CE-marked and is currently marketed in select countries in Europe. The acquisition will help Philips to further expand its leadership position in the growing home care market, and its ability to deliver integrated solutions that drive efficiencies and improved outcomes. Philips already offers a broad range of care solutions for people living with obstructive sleep apnea.

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in digital health, medtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10. September 2025

Gilde Healthcare ernennt Dr. Christian Stark zum Group CEO ihrer global operierenden Medizintechnikgruppe

Die Medizintechnikgruppe, zu der zwei Hersteller chirurgischer Instrumente aus der Region Tuttlingen gehören, Koscher & Würtz und Christian Diener, hat Dr. Christian Stark mit Wirkung zum 1. September 2025 zum Chief Executive Officer (CEO) berufen....
3. September 2025

Gilde Healthcare company SynOx Therapeutics Completes Enrollment in Registrational Trial Significantly Ahead of Timeline

DUBLIN, IRELAND, OXFORD, UK, and PHILADELPHIA, PA -- August 5th, 2025 – SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced completion of patient enrolment...
5. August 2025